ArrowMark Colorado Holdings’s Nurix Therapeutics NRIX Stock Holding History

ArrowMark Colorado Holdings’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.88M	Hold	314,762	–	–	0.13%	177
2025 Q4	$5.97M	Hold	314,762	–	–	0.13%	181
2025 Q3	$2.91M	Hold	314,762	–	–	0.05%	216
2025 Q2	$3.59M	Hold	314,762	–	–	0.06%	206
2025 Q1	$3.74M	Hold	314,762	–	–	0.06%	196
2024 Q4	$5.93M	Hold	314,762	–	–	0.08%	181
2024 Q3	$7.07M	Hold	314,762	–	–	0.09%	162
2024 Q2	$6.57M	Hold	314,762	–	–	0.08%	179
2024 Q1	$4.63M	Hold	314,762	–	–	0.05%	217
2023 Q4	$3.25M	Hold	314,762	–	–	0.04%	218
2023 Q3	$2.47M	Buy	+314,762	New	+$2.87M	0.03%	225

Other funds holding NRIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

ArrowMark Colorado Holdings's NRIX Position: Q1 2026 in Review

ArrowMark Colorado Holdings held its Nurix Therapeutics (NRIX) position steady in Q1 2026 at 314,762 shares worth $4.88M. The position accounts for 0.13% of the portfolio, ranked #177.

ArrowMark Colorado Holdings first reported a position in NRIX in Q3 2023 and has held it in 11 quarters since. The position peaked at $7.07M in Q3 2024. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

ArrowMark Colorado Holdings held 314,762 shares of Nurix Therapeutics worth $4.88M as of Q1 2026.
ArrowMark Colorado Holdings left its Nurix Therapeutics share count unchanged in Q1 2026.
Nurix Therapeutics made up 0.13% of ArrowMark Colorado Holdings's portfolio in Q1 2026, its #177 holding.
ArrowMark Colorado Holdings first reported a position in Nurix Therapeutics in Q3 2023 and has held it in 11 quarters since.
ArrowMark Colorado Holdings's Nurix Therapeutics position peaked at $7.07M in Q3 2024.
195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on ArrowMark Colorado Holdings's 13F filing for Q1 2026, filed 15 May 2026.